From research into the single-chain antibody structures found in camelids (camels and other animals), Ordaos Bio is trying to harness the potential of mini-proteins, a new category that combines some of the best features of small molecules and antibodies, while minimizing some of those modalities’ limitations.
The New York biotech, which just raised a $5m seed funding and hopes to put together a series A round in the next 18 months, is working with partners to design protein therapeutics with optimal
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?